

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

4

	Complete if Known					
Application Number 10/814,634						
Filing Date	April 1, 2004					
First Named Inventor	Tania KASTELIC					
Art Unit	1636					
Examiner Name	C. Qian					
Attorney Docket Number	608352000100					

	U.S. PATENT DOCUMENTS						
Eveni	Examiner Cite		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Initiats	•	Cite No.	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
$\Box$ 0	.Q	<b>/</b> 1.	US-2004/0214223-A1	10-28-2004	Cao et al.		
		2.	US-2005/0048549-A1	03-03-2005	Cao et al.		
		3.	US-5,444,149-A	08-22-1995	Keene et al.		
		4.	US-5,587,300-A	12-24-1996	Malter		
		5.	ÜS-5,698,427-A	12-16-1997	Keene et al.		
		6.	US-5,731,343-A	03-24-1998	Feng et al.		
	1	7.	<b>№S-6,635,671-B1</b>	10-21-2003	Kastelic et al.		
		8.	US-7,078,171-B2	07-18-2006	Giordano et al.		

		FOREI	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Palentee or	Peges, Columns, Lines,	
Initials*	No.	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	⊤ಿ
/C.Q	Θ.	GB-9828707.1	02-17-1999	Novation Pharmaceuticals, Inc.		
	10.	GB-9828710.5	02-17-1999	Novation Pharmaceuticals, Inc.		
	11.	WO-93/20212-A1	10-14-1993	The Government of the United States of America as represented by The Secretary, Department of Health and Human Services		
	12.	WO-95/33831-A1	12-14-1995	Creative Biomolecules, Inc.		
	13.	WO-98/39484-A1		Scriptgen Pharmaceuticals, Inc.		
	14.	WO-00/39314-A1	07-06-2000	Novation Pharmaceuticals, Inc.		
_	15.	WO-2004/065561-A2	08-05-2004	PTC Therapeutics, Inc.		

"EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspip.gog/">www.uspip.gog/</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must procede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
/C.Q./	16.	<ol> <li>Akashi, M. et al. (1994). "Number and Location of AUUUA Motifs: Role in Regulating Transiently Expressed RNAs," Blood 83:3182-3187.</li> </ol>				
	17.	Auwerx, J. (1991). "The Human Leukemia Cell Line, THP-1: A Multifaceted Model for the Study of Monocyte-Macrophage Differentiation," Experiente 47:22-31.				
	18.	Banholzer, R. et al. (June 1997). "Rapamycin Destabilizes Interleukin-3 mRNA in Autocrine Tumor Cells by a Mechanism Requiring an Intact 3' Untranslated Region," <i>Molecular and Cellular Biology</i> 17(6):3254-3260.				
V	19.	Bernstein, P.L. et al. (April 1992). "Control of c-myc mRNA Half-Life in vitro by a Protein Capable of Binding to a Coding Region Stability Determinant," Genes Dev. 6(4):642-654.				

Examiner /Celine Qian/	Date Considered 07/31/2007
no 1121240	

C.,	Substitute for form 1449/PTO			Complete if Known		
Sut	osulule for form 1449/PTO			Application Number	10/814,634	
1 10	NFORMATION	l DI	SCLOSURE	Filing Date	April 1, 2004	
•	STATEMENT BY APPLICANT			First Named Inventor	Tania KASTELIC	
~				Art Unit	1636	
	(Use as many sheets as necessary)			Examiner Name	C. Qian	
Sheet	2	of	4	Attorney Docket Number	608352000100	

/C.Q	<i>2</i> 0.	Beutler, B. et al. (1988). "Assay of a Ribonuclease That Preferentially Hydrolyses mRNAs Containing Cytokine-Derived UA-Rich Instability Sequences," <i>Biochem. Biophys. Res. Comm.</i> 152:973-980.
	21.	Chen, CY.A. et al. (1994). "Interplay of Two Functionally and Structurally Distinct Domains of the c-fos AU-Rich Element Specifies Its mRNA-Destabilizing Function," <i>Mol. Cell. Biol.</i> 14:416-426.
	22.	Chen, CY.A. et al. (1994). "Selective Degradation of Early-REsponse-Gene mRNAs: Functional Analyses of Sequence Features of the AU-Rich Elements," <i>Mol. Cell. Biol.</i> 14:8471-8482.
	23.	Chen, CY.A. et al. (1995). "AU-Rich Elements: Characterizatiopn and Importance in mRNA Degradation," TIBS 20:465-470.
	24.	Chen, CY.A. et al. (1995). "mRNA Decay Mediated by Two Distinct AU-Rich Elements from c-fos and Granulocyte-Macrophage Colony-Stimulating Factor Transcripts: Different Deadenylation Kinetics and Uncoupling from Translation," Mol. Cell. Biol. 15:5777-5788.
	25.	Claffey, K.P. et al. (February 1998). "Identification of a Human VPF/VEGF 3' Untranslated Region Mediating Hypoxia-Induced mRNA Stability," <i>Mol. Biol. Cell</i> 9:469-481.
	26.	Cleveland, D.W. et al. (November 1989). "Multiple Determinants of Eukaryotic mRNA Stability," New. Biol. 1(2):121-126.
	27.	Crawford, E.K. et al. (August 1997). "The Role of 3' Poly(A) Tail Metabolism in Tumor Necrosis Factor-a Regulation," <i>J. Biol. Chem.</i> 272:21120-21127.
	28.	Danner, S. et al. (February 1998). "Agonist REgulation of Human β <sub>2</sub> -Adrenergic Receptor mRNA Stability Occurs via a Specific AU-Rich Element," <i>J. Biol. Chem.</i> 273:3223-3229.
	29.	Fan, X.C. (June 1998). "Overexpression of HuR, a Nuclear-Cytoplasmic Shuttling Protein, Increases the <i>in vivo</i> stability of ARE-Containing mRNAs," <i>EMBO J.</i> 17:3448-3460.
	30.	GenBank Accession No. AF022375, created October 7, 1998, located at <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=3719220">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=3719220</a> , last visited on February 7, 2007, two pages.
	31.	GenBank Accession No. D10493, created May 29, 2002, located at <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&amp;val=219932">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&amp;val=219932</a> , last visited on February 7, 2007, seven pages.
	32.	GenBank Accession No. M13994, created October 31, 1994, located at <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=179366">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=179366</a> , last visited on December 29, 2006, three pages.
	33.	GenBank Accession No. U40398, created March 13, 1997, located at <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=1117909">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=1117909</a> , last visited on December 29, 2006, three pages.
	34.	GenBank Accession No. X04500, created November 14, 2006, located at <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=33788">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=33788</a> , last visited on December 29, 2006, six pages.
	35.	GenBank Accession No. Y00264, created September 12, 1993, located at <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=28525">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=28525</a> , last visited on December 29, 2006, three pages.
	36.	Gil, P. et al. (1996). "Multiple Regions of the Arabidopsis SAUR-AC1 Gene Control Transcript Abundance: the 3' Untranslated Region Functions as a mRNA Instability Determinant," EMBO J. 15:1678-1686.
	37.	Heaton, J.H. et al. (June 1998). "Cyclic Nucleotide Regulation of Type-1 Plasminogen Activator-Inhibitor mRNA Stability in Rat Hepatoma Cells," J. Biol. Chem. 273:14261-14268.
	38.	International Search Report mailed June 6, 2000, for PCT Application No. PCT/CA99/01235 filed December 23, 1999, three pages.
V	39.	Kastelic, T. et al. (October 1996). "Induction of Rapid IL-1B mRNA Degradation in Thp-1 Cells Mediated Through the AU-rich Region in the 3' UTR by a Radcicol Analogue," <i>Cytokine</i> 8(10):751-761.

	***		
Examiner 1	(Calina Olan)	Date	07/24/2007
Signature	/Celine Qian/		I 07/31/2007 <b>I</b>
Signature		Considered	

Sut	Substitute for form 1449/PTO		Complete if Known		
350	saudie for form 1448/FTO			Application Number	10/814,634
11	NFORMATION	i Di	SCLOSURE	Filing Date	April 1, 2004
ı	STATEMENT BY APPLICANT			First Named Inventor	Tania KASTELIC
				Art Unit	1636
<u> </u>	(Use as many sheets as necessary)			Examiner Name	C. Qian
Sheet	3	of	4	Attorney Docket Number	608352000100

/C.Q./	40.	Klausner, R.D. et al. (1993). "Regulating the Fate of mRNA: The Control of Cellular Iron Metabolism," Cell 72:19-28.
	41.	Kobayashi, M. et al. (July 1998). "Characterization of the 3' Untranslated Region of Mouse DNA Topoisomerase Ila mRNA," Gene 215:329-337.
	42.	Lagnado, C.A. et al. (1994). "AUUUA Is Not Sufficient to Promote Poly(A) Shortening and Degradation of an mRNA: The Functional Sequence Within AU-Rich Elements May Be UUAUUUA(U/A)(U/A)," Mol. Cell. Biol. 14:7984-7995.
	43.	Levy, A.P. et al. (1996). "Post-Transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia," J. Biol. Chem. 271:2746-2753.
	44.	Levy, J.R. et al. (1995). "Sequence and Functional Characterization of the Terminal Exon of the Human Insulin Receptor Gene," <i>Biochim. Biophys. Acta</i> 1263:253-257.
	45.	Lewis, T. et al. (May 1998). "Mapping of a Minimal AU-Rich Sequence Required for Lipopolusaccharide-Induced Binding of a 55-kDa Protein on Tumor Necrosis Factor-a mRNA," J. Biol. Chem. 273:13781-13786.
	46.	Mitchell, P. et al. (April 2000). "mRNA Stability in Eukaryotes," Curr. Opin. Genet. Dev. 10:193-198.
	47.	Mitchell, P. et al. (June 2001). "mRNA Tumover," Curr. Opin. Cell. Biol. 13(3):320-325.
	48.	Nanbu, R. et al. (1994). "Multiple Instability-Regulating Sites in the 3' Untranslated Region of the Urokinase-Type Plasminogen Activator mRNA," <i>Mol. Cell. Biol.</i> 14:4920.
	49.	Ross, J. (September 1995). "mRNA Stability in Mammalian Cells," <i>Microbiol. Rev.</i> 59(3):423-450.
	50.	Sachs, A.B. (1993). "Messenger RNA Degradation in Eukaryotes," Cell 74:413-421.
	51.	Sambrook, J. et al. (1989). "Calcium Phosphate-Mediated Transfection of Adherent Cells in Suspension" In Chapter 16 In Molecular Cloning A Laboratory Manual, Cold Spring Harbor Labortory Press: Cold Spring Harbor, NY, pg. 16.37.
	52.	Sambrook, J. et al. (1989). "Standard Protocol for Calcium Phosphate-Mediated Transfection of Adherent Cells" In Chapter 16 In Molecular Cloning A Laboratory Manual, Cold Spring Harbor Labortory Press: Cold Spring Harbor, NY, pp. 16.33-16.36.
	53.	Shaw, G. et al. (1986). "A Conserved AU Sequence from the 3' Untranslated Region of GM- CSF mRNA Mediates Selective mRNA Degradation." Cell. 46:659-667.
	54.	Shyu, AB. et al. (1991). "Two Distinct Destabilizing Elements in the c-fos Message Trigger Deadenylation as a First Step in Rapid mRNA Decay," Genes & Development 15:221-231.
	55.	Staton, J.M. et al. (August 2000). "Hormonal Regulation of mRNA Stability and RNA-Protein Interactions in the Pituitary," <i>J. Mol. Endocrinology</i> 25(1):17-34.
1 I I	56.	Stoecklin, G. et al. (1994). "Functional Hierarchy of AUUUA Motifs in Mediating Rapid Interleukin-3 mRNA Decay," <i>J. Biol. Chem.</i> 269:28591-28597.
	57.	Stolle, C.A. et al. (1988). "Cellular Factor Affecting the Stability of β-Globin mRNA," Gene 62:65-74.
	58.	Sullivan, M.L. et al. (1996). "Mutational Analysis of the DST Element in Tobacco Cells and Transgenic Plants: Identification of Residues Critical for mRNA Instability," RNA 2:308-315.
	59.	Wilusz, C.J. et al. (April 11, 2001). "The Cap-To-Tail Guide to mRNA Turnover," Nat. Rev. Mol. Cell. Biol. 2(4):237-246.
	60.	Winstall, E. et al. (1995). "Rapid mRNA Degradation Mediated by the <i>c-fos</i> 3' AU-Rich Element and That Mediated by the Granulocyte-Macrophage Colony-Stimulating Factor 3' AU-Rich Element Occur Through Similar Polysome-Associated Mechanisms," <i>Mol. Cell. Biol.</i> 15:3796-3804.
	61.	Xu, N. et al. (August 1997). "Modulation of the Fate of Cytoplasmic mRNA by AU-Rich Elements: Key Sequence Features Controlling mRNA Deadenylation and Decay," <i>Mol. Cell. Biol.</i> 18:4611-4621.
W	62.	Zhang, G. et al. (October 23, 1996). "An Enhanced Green Fluorescent Protein Allows Sensitive Detection of Gene Transfer in Mammalian Cells," <i>Biochemical and Biophysical Research Communications</i> 227(3):707-711.

Examiner Signature	/Celine Qian/	Date Considered 0	7/31/2007
		Todiladica	

Sub	Substitute for form 1449/PTO			Complete if Known		
300		O		Application Number 10/814,634		
IN	FORMATIO	ON DI	SCLOSURE	Filing Date	April 1, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Tania KASTELIC	
	.,		AI I LIOAIII	Art Unit	1636	
	(Use as many sheets as necessary)			Examiner Name	C. Qian	
Sheet	4	of	4	Attorney Docket Number	608352000100	

/C.Q./63.	Zhang, S. et al. (1995)."Indentification and Characterization of a Sequence Motif Involved in	
	Nonsense-Mediated mRNA Decay," Mol. Cell. Biol. 15:2231-2244.	
	Zubiaga, A.M. et al. (April 1995). "The Nonamer UUAUUUAUU Is the Key AU-Rich Sequence	
10.00	Motif That Mediates mRNA Degradation," Molecular and Cellular Biology 15(4):2219-2230.	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.